Achieving Treat-to-Target Goals in Systemic Lupus Erythematosus

Because of its varied, changing, and sometimes subtle manifestations, systemic lupus erythematosus (SLE) is notably difficult to manage. It is thus essential to ensure that, once an SLE diagnosis has been established, disease activity measures are applied consistently and uniformly. Because SLE is associated with cumulative permanent organ damage that leads to significant morbidity and mortality, treatment should aim to prevent organ damage and to optimize health-related quality of life by controlling disease activity and minimizing comorbidities and drug toxicity.

In this activity, learners will meet two patients: Amy, a new mother with a history of SLE who has been experiencing foot and ankle swelling, and Maria, a teenage girl with left knee swelling. The activity examines strategies for monitoring SLE disease activity and damage, as well as guideline-driven recommendations for treating SLE and managing treatment side effects to optimize patient outcomes.